Drug discovery

#Drug discovery #Events #Protein misfolding

Wren Therapeutics & University of Florida at Targeting Protein Misfolding 2021

In the field of drug discovery, so called ‘undruggable’ targets are like the stubborn children of the protein world – notoriously difficult to find, and even harder to target. For undruggable protein misfolding diseases such as Alzheimer’s and Parkinson’s, traditional drug discovery and biological approaches have, to date, proved largely… Read More

#News

#Drug development #Drug discovery #Gene therapy #Therapeutics

Geneticist launches Axovia Therapeutics to develop medicines for ciliopathies

Axovia Therapeutics, a gene therapy company developing disease-transformative medicines for ciliopathies, led by researcher Professor Philip Beales, has launched after being in stealth mode for the past year. Axovia is a majority-owned subsidiary of Jaguar Gene Therapy, and is partially funded by UCL Technology Fund. Axovia is receiving initial operational… Read More

#Editor's Choice #News

#Diagnostics #Drug development #Drug discovery #Webinar

Why hepatocytes are enabling antimalarial drug discovery

BioIVT, providers of research models and services for drug and diagnostic development, will be hosting a webinar where researchers from the University of Georgia will explain the first medium-throughput, 384-well plate-based liver-stage antimalarial drug discovery platform which they have developed. The webinar, entitled Identifying the Critical Factors Enabling a Phenotypic… Read More

#News

#Coronavirus #Covid-19 #Drug development #Drug discovery #Immunology / Virology & Vaccines #Pandemic #Sitting Down With #Therapeutics

How critical is the part therapeutics have to play in the pandemic?

This DDW Sponsored Sitting Down With episode features Guy Goldberg, Chief Business Officer of RedHill Biopharma. In this episode  – Guy Goldberg discusses COVID-19 therapeutics and their role in the pandemic. Goldberg shares his market insight, the benefits of an orally-administered small molecule tablet for COVID treatment and how the… Read More

#Podcasts

#AI / data analytics / healthtech / informatics #Chromatography #Drug discovery

Waters and TetraScience partner to deliver access and insights for chromatography data

Waters Corporation has entered a reseller agreement with TetraScience, a cloud technology innovator for life sciences R&D. Through the partnership, Waters will offer its customers the Empower Data Science Link, powered by TetraScience. This technology pairs Waters’ compliance-ready Empower Chromatography Data System (CDS) with TetraScience’s Data Platform and data science… Read More

#News

#Biotechnology #Coronavirus #Covid-19 #Drug development #Drug discovery #Metabolomics #Metabolon #Narrated podcasts #Pharmaceutical

The potential of metabolomics & COVID-19 Vaccine Development

Today’s episode is titled The potential of metabolomics & COVID-19 Vaccine Development, and covers 2 articles taken from the most recent Fall issue of DDW. These articles are titled: Why metabolomics has the potential to transform diagnosis and treatment. & COVID-19 Vaccine Development: dethroning evil King Coronavirus These articles were firstly… Read More

#Podcasts

#Drug discovery #Events

Research & Innovation 2021 virtual

ELRIG’s virtual event  will take place on 23 and 24 February and will cover therapeutic innovation for the new decade. Research and Innovation 2021 will delve into the following four key scientific areas: Innovations in structural biology & biophysics; The rise of immunology across drug discovery; Seeking novel drug targets for the discovery… Read More

#News

#Biotechnology #Drug development #Drug discovery

Quotient Sciences CEO talks acquisitions, efficiency and finding cures fast

Mark Egerton, Chief Executive Officer, Quotient Sciences, spoke to Lu Rahman about the company’s acquisition of Arcinova and what it means for the drug discovery sector. Quotient Sciences, the drug development and manufacturing accelerator, recently acquired Arcinova, the UK-based multiservice contract development and manufacturing organisation (CDMO). Boasting over 40 years of… Read More

#Editor's Choice #News #Trending News

#AI / data analytics / healthtech / informatics #Clinical trials #Drug discovery #Pharmaceuticals #Rare disease #Therapeutics

The move towards patient-powered, data-driven rare disease drug discovery

By Rayne Rodgers, Vice President and Executive Director of MOVR for Muscular Dystrophy Association (MDA), and Sharon Hesterlee MDA’s Executive Vice President and Chief Research Officer. As an umbrella organisation representing those living with more than 40 types of neuromuscular disorders, the Muscular Dystrophy Association (MDA) contributes significantly to innovations… Read More

#Editor's Choice #Exclusive Content #News

#Drug discovery

New method for asymmetric N,N-acetal synthesis could advance drug development

Scientists identify new method of preparing N,N-acetals with high enantiopurity using diketones, crowning a new approach to synthesising bioactive drugs. Chiral N,N-acetals are an important component of several bioactive drugs and medicines. Owing to this, chemical reactions that lead to high-purity yield of the desired ‘enantiomeric’ form are highly sought… Read More

#Exclusive Content #News

#AI / data analytics / healthtech / informatics #Drug discovery #Therapeutics

Exscientia and University of Oxford partner on AI-driven Alzheimer’s treatments

Exscientia, an AI drug discovery company, has announced its collaboration with the Alzheimer’s Research UK University of Oxford Drug Discovery Institute (ARUK-ODDI) to develop medicines targeting neuroinflammation for the treatment of Alzheimer’s disease (AD). AD is the most common form of dementia worldwide, with an estimated 44 million people living… Read More

#Editor's Choice #News

#AI / data analytics / healthtech / informatics #Drug discovery

Optibrium investment will boost computer-aided drug discovery

Optibrium, developer of software for drug discovery, has raised significant investment from Kester Capital, a private equity firm typically. The funding  should accelerate the development of the business through organic growth and acquisition. Currently, more than 150 organisations worldwide deploy Optibrium’s technology in their research programs, including five of the… Read More

#News

#AI / data analytics / healthtech / informatics #Drug development #Drug discovery #Gene therapy #Life sciences #Narrated podcasts #Stem cells

The power of precision and the potential of human tissue chips

Today’s episode is titled: The power of precision and the potential of human tissue chips, and covers 2 articles taken from the most recent issue of DDW. These articles are titled: The power of precision to keep biologics effective and safe & Why we should be interested in human tissue chips These… Read More

#Podcasts

#Biomarkers #Drug candidates #Drug development #Drug discovery #Hits #Target validation

Evotec and Related Sciences form drug discovery and development partnership

Evotec has entered into an integrated multi-target drug discovery agreement with biotech venture creation firm Related Sciences to generate multiple drug development candidates, biomarkers, and IND filings over a multi-year period. Evotec and Related Sciences will jointly discover and develop a range of therapeutic approaches for clearly defined patient populations… Read More

#Editor's Choice #News

#Antibodies #Drug discovery

Flow Eighteen38, a new protein sciences service

FairJourney Biologics (FJB) and IONTAS, specialists in the discovery and optimisation of antibodies, have launched of a new protein sciences division, Flow Eighteen38. The new business unit has been introduced to accelerate customer antibody research projects, by delivering reagents, purified proteins, and characterisation data on antibody panels and leads. As… Read More

#News

#Assay development & optimisation #Drug discovery #Therapeutics

PerkinElmer launches assay kits to help advance therapeutics discovery

PerkinElmer has announced the addition of new assay kits to help further GPCR (G Protein-Coupled Receptor) therapeutic discovery. The new offerings extend the company’s GPCR analysis portfolio, which includes assays, plate readers, automation technologies and software solutions combined with siRNA, shRNA, CRISPR, and cDNA/ORF libraries to help scientists more easily… Read More

#News